Preliminary results of a phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology (NSCLC-NS) with disease progression after a bevacizumab (bev) ...
For the first time, weekly cisplatin plus radiotherapy (CDDP+RT) has been shown to be not only less toxic than dosing once every three weeks but also achieves better outcomes in patients with ...
Concomitant pemetrexed/carboplatin chemotherapy and 3D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy for locally advanced non-small cell lung cancer: Preliminary ...